Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

A Look At Which Multiple Myeloma ASCO News Seemed Most Important To General Cancer Related Sites

Home/Uncategorized/A Look At Which Multiple Myeloma ASCO News Seemed Most Important To General Cancer Related Sites

A Look At Which Multiple Myeloma ASCO News Seemed Most Important To General Cancer Related Sites

Medpage Today just ran an article about anti-cancer related advances from ASCO.  I always find it interesting to take a look at what more general cancer related sites consider noteworthy about the world of multiple myeloma.  This extensive article only featured one myeloma related study from ASCO:

CHICAGO — A chemical cousin to the infamous drug thalidomide sharply cut recurrence of multiple myeloma in a prospective randomized trial, a researcher said.

Maintenance therapy with lenalidomide (Revlimid) after autologous stem-cell transplant reduced the risk of recurrence by 54% after three years, compared with placebo, according to Michel Attal, MD, of Purpan Hospital in Toulouse, France.

Here is a link to the article about how  Revlimid maintenance therapy showed impressive results in this three year French study.

Feel good and keep smiling!  Pat